This site is intended for US residents only
This site is intended for US residents only.
  •  
  • COMPANY ▾
    • TEVA GLOBAL
    • VISION + VALUES
    • HISTORY
    • SPECIALTY AREAS
      • CNS
      • Oncology
      • Respiratory
      • Select Brands
      • Women's Health
    • GOVERNMENT AFFAIRS
    • CONTACT
  • MEDICINES ▾
    • SPECIALTY MEDICINES
    • GENERIC MEDICINES
    • MEDICAL AFFAIRS
      • Medical Information
      • Medical Education
    • QUALITY + SAFETY
    • TRADE PARTNERS
      • Return Goods Policy
      • Terms and Conditions
      • ADR Products
  • RESPONSIBILITY ▾
    • CORPORATE SOCIAL RESPONSIBILITY
      • Corporate Charitable Donations
      • Access to Medicine
      • Volunteerism
    • ADVOCACY
    • COMPLIANCE
    • RELATIONSHIPS WITH HCPs
  • CAREERS ▾
    • SEARCH JOBS
    • CAREERS FAQ
    • THE TEVA EXPERIENCE
    • TESTIMONIALS
  • NEWS ▾
    • MEDIA CONTACTS
    • FAST FACTS
    • MEDIA FAQ
Who We Are Medicines Integrity Values Careers
Teva for your whole life.

TEVA PHARMACEUTICALS IN THE US

Teva is working every day to make quality healthcare accessible. As a manufacturer of specialty and generic pharmaceuticals, Teva provides both new and innovative therapies and greater access to affordable medicines.


Learn more ▸

MEDICINES THAT FIT EVERYONE'S NEEDS

One in every eight prescriptions dispensed in the US is a Teva product.*

*IMS Health NPA MAT June 2014


Explore Generics

▸


Explore All Medicines

▸

NEWS

1.26.15Teva Receives FDA Approval for First Generic Nexium® Delayed-Release Capsules in the United States
1.20.15Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
1.15.15Teva to Report Fourth Quarter 2014 Financial Results on February 5, 2015
1.8.15Teva to Present at the 33rd Annual J.P. Morgan Healthcare Conference
1.6.15Teva Launches Generic Diovan® in the United States
12.23.14FDA Approves Teva’s GRANIX® (tbo-filgrastim) Injection for Self-Administration
12.22.14Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
12.19.14Teva Announces FDA Approval of QNASL® (Beclomethasone Dipropionate) Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis
12.11.14Teva Provides 2015 Business Outlook
12.10.14Teva Announces Launch of First Generic Celebrex® Capsules in the United States
More ▸
© Copyright 2014 Teva Pharmaceuticals USA
Supplier Portal   |   Privacy   |    Legal   |   Contact   |    Sitemap
COMPANY

 MEDICINES

 RESPONSIBILITY
TEVA GLOBAL

VISION + VALUES

HISTORY

SPECIALTY AREAS

GOVERNMENT
AFFAIRS

CONTACT 		SPECIALTY MEDICINES

GENERIC MEDICINES

MEDICAL AFFAIRS

QUALITY + SAFETY

TRADE PARTNERS 		CORPORATE SOCIAL
RESPONSIBILITY

ADVOCACY

COMPLIANCE

RELATIONSHIPS WITH HCPs
CAREERS

 NEWS
CAREERS FAQ

THE TEVA EXPERIENCE

TESTIMONIALS 		MEDIA CONTACTS

FAST FACTS

MEDIA FAQ